OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region

Mediplexus will offer U.S.-sourced healthcare data alongside its Korean data for customers’ research and development needs.

Rhea-AI Summary

OneMedNet (ONMD) signed its 11th channel partner agreement with Mediplexus, establishing a distribution channel for its healthcare data in Korea.

Mediplexus, a subsidiary of Korean contract research organization C&R Research, will distribute OneMedNet’s U.S.-sourced Real World Data—data collected from healthcare delivery—alongside its own Korean healthcare data. The agreement extends OneMedNet’s commercial reach into the broader Asia Pacific region. The companies plan to broaden the collaboration in stages after an initial one-year engagement. Mediplexus plans to combine the data with analysis, model validation and regulatory support to help Korean medical device and medical AI companies enter the U.S. market.

2 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point11th channel partner agreement appoints Mediplexus as Korean distributor, extending OneMedNet’s reach into Asia Pacific.
• Minor point. Forward-looking: it has not happened yet and may not happen.Collaboration expansion is planned in stages following the initial one-year engagement.

Negative

• None.

Key Figures

Channel partner number: 11th channel partner Initial engagement: One year Patient journeys: Exceeding 90 million +2 more

Channel partner number

11th channel partner

Mediplexus agreement

Initial engagement

One year

The collaboration may broaden in stages afterward

Patient journeys

Exceeding 90 million

OneMedNet iRWD network

Studies

270 million

OneMedNet iRWD network

Healthcare partner sites

More than 2,300

OneMedNet iRWD network

Historical Context

1 past event · Latest: Sep 30

1 event

1. Sep 30

   Channel partner agreement

   24h Move

   +11.5%

   Tenth channel partner agreement disclosed seven-figure multiyear terms and incremental annual sublicensing revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rwd, rwe, cro, eeg, +1 more

5 terms

rwd medical

"Real World Data (RWD)"

Real-world data (RWD) are health and medical information collected outside controlled clinical trials—such as electronic health records, insurance claims, patient registries, wearable devices, and pharmacy records. For investors, RWD is like seeing how a product performs on city streets versus a test track: it reveals how treatments work in everyday practice, helps predict market uptake, supports regulatory and reimbursement decisions, and can reduce uncertainty about a therapy’s real-world value.

rwe medical

"Real World Evidence (RWE)"

Real-world evidence (RWE) is clinical or health-related information derived from real-world data—such as electronic health records, insurance claims, patient registries, or wearable devices—used to draw conclusions about how a medical product performs outside controlled clinical trials. RWE is generated by observational studies, pragmatic trials, or retrospective analyses and can complement randomized controlled trials by showing effectiveness, safety, or usage patterns in broader, routine-care populations; because it comes from non-randomized sources it may be subject to biases and confounding that must be addressed with study design and statistical methods.

cro technical

"contract research organizations (CROs)"

CRO stands for Contract Research Organization, a company that helps pharmaceutical and biotech firms manage and carry out clinical trials to test new medicines. For investors, CROs are important because they enable drug companies to develop new treatments more efficiently, potentially accelerating the path to market and affecting the company's growth prospects and success.

eeg medical

"radiology, cardiology, EEG, and ECG"

An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.

ecg medical

"radiology, cardiology, EEG, and ECG"

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agreement with Mediplexus, a subsidiary of Korean CRO C&R Research, establishes a new Asia Pacific distribution channel for OneMedNet’s first-party, direct-from-source multimodal Real World Data

MINNEAPOLIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced its 11^th channel partner agreement with Mediplexus, a healthcare data company specializing in RWD and Real World Evidence (RWE) and a subsidiary of C&R Research, one of Korea’s leading contract research organizations (CROs). Under the agreement, OneMedNet will supply its U.S.-sourced Real World Data to Mediplexus, its appointed distributor in Korea – extending OneMedNet’s commercial reach into the broader Asia Pacific region. The companies plan to broaden the scope of the collaboration in stages following an initial one-year engagement.

Through the agreement, Mediplexus will offer OneMedNet’s U.S sourced healthcare data alongside its own Korean healthcare data, each delivered in a form tailored to the customer’s purpose — significantly widening the field on which Korean biopharma, medtech and medical AI companies can pursue global clinical trials, RWD and RWE research, drug development, and medical AI initiatives. Mediplexus plans to pair OneMedNet’s data with analysis, model validation, and regulatory and market-access support to help Korean medical device and medical AI companies enter the U.S. market.

OneMedNet’s iRWD™ network — now exceeding 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites — delivers multimodal data spanning radiology, cardiology, EEG, and ECG, together with de-identified electronic health records. The data is sourced directly from healthcare providers, not intermediaries or secondary markets, and de-identified at the source.

The agreement comes as the global regulatory environment increasingly moves toward formal acceptance of RWD and RWE. Both the U.S. FDA and the European EMA encourage the use of RWE, and following the adoption of the ICH M14 guideline¹ in 2025, the global RWE solutions market is projected to grow from USD 5.4 billion in 2025 to USD 10.8 billion by 2030².

“Asia Pacific is expected to register the fastest growth in the RWE solutions market, driven by expanding healthcare data infrastructure²” said Aaron Green, President & CEO of OneMedNet. “This agreement puts our first-party, direct-from-source multimodal data into the hands of a partner with deep clinical research roots in the region. Mediplexus and C&R Research bring the local expertise, relationships, and regulatory know-how to make our data actionable for Korean innovators and this initial engagement is structured to expand in both scope and geography over time.”

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the planned expansion to the Asia Pacific market and related expectations, projected market growth, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

1. https://www.ich.org/page/multidisciplinary-guidelines#14-1
2. https://www.marketsandmarkets.com/Market-Reports/real-world-evidence-solution-market-76173991.html

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does OneMedNet’s distribution agreement with Mediplexus cover?

OneMedNet will supply its U.S.-sourced Real World Data to Mediplexus, its appointed distributor in Korea. Mediplexus will offer that data alongside its Korean healthcare data, tailored to customers’ purposes. The companies plan to broaden the collaboration in stages after an initial one-year engagement.